US OptionsDetailed Quotes

CLLS241220C5000

Watchlist
  • 0.05
  • 0.000.00%
15min DelayClose Dec 20 16:00 ET
0.00High0.00Low
Intraday
  • 5D
  • Daily

News

Comments

    Jaguar8
    Jaguar8
    Nov 5 15:31
    NEWS
    $Cellectis (CLLS.US)$
    Cellectis Presents Multiple Strategies to Enhance CAR T-cell Efficacy in Solid Tumors at the SITC Annual Meeting
    Cellectis announced pre-clinical data presentation at SITC's 39th Annual Meeting, showcasing strategies to enhance CAR T-cell efficacy against solid tumors. The research focuses on overcoming challenges in the tumor microenvironment (TME) using TALEN®-mediated gene editing to generate allogeneic CAR T-cells. The company developed two key approaches: a FAP-depe...
    Jaguar8
    Jaguar8
    Nov 4 22:08
    ER THIS AM
    $Cellectis (CLLS.US)$
    Cellectis Provides Business Updates and Financial Results for Third Quarter 2024
    Positive
    Strong cash position of $264 million with runway extended into 2027
    Significant revenue increase to $34.1 million, up from $7.2 million YoY
    Net loss improved to $42.7 million from $59.3 million YoY
    Secured $47 million in payments from AstraZeneca partnership
    Negative
    R&D expenses increased to $69.7 million from $62.7 million YoY
    SG&A expenses rose to $14.2 million from $12....
    Trytosaveabit
    Trytosaveabit
    Nov 4 17:01
    Expected more of a move! Hehehe
    $Cellectis (CLLS.US)$ Cellectis GAAP EPS of -$0.23 misses by $0.02, revenue of $18.05M beats by $8.95M
    Jaguar8
    Jaguar8
    Oct 22 01:00
    NEWS
    $Cellectis (CLLS.US)$
    Cellectis to Present Data on TALE-Base Editors and Non-Viral Gene Therapy at the ESGCT 31st Annual Congress
    Cellectis, a clinical-stage biotechnology company, will present pre-clinical data on TALE base editors (TALEB) and non-viral gene insertion at the European Society of Cell and Gene Therapy 31st annual congress in Roma, Italy, from October 22-25, 2024. Two posters will be showcased:
    1. 'Controlling C-to-T editing with TALE base editors' by Alexandre Juillerat, Ph.D....
    Trytosaveabit
    Trytosaveabit
    Sep 3 15:36
    Update
    $Cellectis (CLLS.US)$ Benzinga· 4 mins ago
    Cellectis Presents Pre-Clinical Evidence That TALEN-Edited MUC1 CAR T-Cells Reduce Triple-Negative Breast Cancer While Ensuring Safety
Read more